Showing 2241-2250 of 5616 results for "".
Agitation in Alzheimer’s Dementia: From Expert Consensus to Clinical Practice
https://reachmd.com/programs/medical-industry-feature/agitation-alzheimers-dementia-expert-consensus-clinical-practice/36262/Nearly half of patients living with dementia due to Alzheimer’s disease will experience agitation during the course of illness.1 In June 2025, expert panel recommendations on identifying and managing agitation in Alzheimer’s dementia were published in Postgraduate Medicine. Learn more about these reDouble Take: Pivotal Data Evaluating PI3K Inhibitor/Endocrine Therapy Regimens in mBC
https://reachmd.com/programs/cme/Double-Take-Pivotal-Data-Evaluating-PI3K-Inhibitor-Endocrine-Therapy-Regimens-in-mBC/37333/Join Drs. Jhaveri and Kalinsky and get up to speed on the latest data on PI3K-directed therapies and their role in the treatment paradigm for HR+, HER2- mBC.ctDNA-Guided Immunotherapy Shows Survival Benefit in MIBC: IMvigor011 Results
https://reachmd.com/programs/project-oncology/ctdna-immunotherapy-survival-mibc-imvigor011/36307/Presented at the 2025 ESMO Congress, the IMvigor011 phase 3 trial evaluated a ctDNA-guided strategy for administering adjuvant atezolizumab in patients with muscle-invasive bladder cancer (MIBC) following radical cystectomy. Patients with high-risk pathological features were monitored using a personBeyond the Colonoscopy: New Screening Guidelines for Colorectal Cancer
https://reachmd.com/programs/project-oncology/beyond-colonoscopy-new-screening-guidelines-colorectal-cancer/9515/Dr. John Kisiel explores updated screening guidelines and novel methods for detecting colorectal cancer.Bridging the Gap in AYA Cure Rates
https://reachmd.com/programs/medical-industry-feature/bridging-the-gap-in-aya-cure-rates/35630/Explore the latest data on asparaginase-based therapies for adolescents and young adults with acute lymphoblastic leukemia and lymphoblastic lymphoma. For US HCPs Only.OCT Biomarkers as Predictors of Treatment Response in RVO-Related Macular Edema
https://reachmd.com/programs/eye-on-ocular-health/oct-biomarkers-as-predictors-of-treatment-response-in-rvo-related-macular-edema/37664/Retinal vein occlusion (RVO) is a leading cause of sudden vision loss, often complicated by macular edema that affects patient outcomes. While treatment options like anti-vascular endothelial growth factor agents and corticosteroid implants exist, predicting response remains a challenge. Hear Dr. MiDual Impact of 4CMenB: Strong Meningococcal B Protection and Waning Gonorrhea Immunity After Five Years
https://reachmd.com/programs/clinicians-roundtable/dual-impact-of-4cmenb-strong-meningococcal-b-protection-and-waning-gonorrhea-immunity-after-five-years/37105/Precision Targeting: Matching CELMoDs to the Right Patient With Myeloma
https://reachmd.com/programs/cme/precision-targeting-matching-celmods-to-the-right-patient-with-myeloma/36569/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma ActivityMS Relapse vs Pseudo-Relapse After Infection: COVID-19 Shows Divergent Risk Pattern
https://reachmd.com/programs/neurofrontiers/program-name/36357/Recognizing Asthma-COPD Overlap: Clinical Clues and Diagnostic Strategies
https://reachmd.com/programs/frontlines-copd/recognizing-asthma-copd-overlap-clinical-clues-and-diagnostic-strategies/35541/Since asthma-COPD overlap syndrome combines features of two distinct respiratory diseases, there’s no single diagnostic test available. And so clinicians must integrate biomarkers and testing strategies from both disease frameworks to properly assess these complex cases. Here to share key strategies